Pfizer and Flynn Pharma are under investigation amid claims they charged “excessive and unfair” prices for a widely-used epilepsy drug in the UK.
The probe by the Competition and Markets Authority is focusing on phenytoin sodium, a drug that has been used to treat epilepsy for decades, which is manufactured by Pfizer but sold in the UK by Flynn Pharma.
It is estimated that around 50,000 people in the UK take phenytoin to control tonic-clonic and focal seizures caused by epilepsy as well as those caused by head trauma or brain surgery.
Pfizer’s brand name for the drug in the UK was Epanutin and according to the CMA the NHS spent around £2.3m on the drug before it sold the UK distribution rights to Flynn Pharma in 2012, which promptly de-branded the product.
Full content: Mail Online
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI